Trending...
- Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
- Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
- Green Revolution CBD Spotlights Its Water-Soluble Focus Tincture With CBD, CBG and Lion's Mane
SYDNEY - Washingtoner -- OncoBeta® GmbH, a medical device company specialising in innovative epidermal radioisotope therapies, today announces the Sydney Brachytherapy Group is the first private clinic in NSW performing Rhenium-SCT® for patients with non-melanoma skin cancers (NMSCs).
Rhenium-SCT® is an advanced radionuclide therapy technology that offers a non-invasive, predominantly single-session treatment with improved cosmetic outcomes for patients suffering from Basal Cell and Squamous Cell Carcinomas (BCCs and SCCs). With the global incidence rates of NMSCs increasing, and more than 7.7 million cases of NMSC being recorded each year1,2, this technology offers patients a new treatment option.
Dr Joseph Gracé, Medical Director of Sydney Brachytherapy Group says, "NMSC is a significant health concern here in Australia (especially for those with Fitzpatrick Skin Types I–III), and we are excited to offer Rhenium-SCT® to our patients with NMSC. The non-invasive nature of this treatment, especially for tumours in hard to reach anatomical locations, is one of the main reasons for using Rhenium-SCT®."
Standard treatments for NMSCs typically require surgery, whereas Rhenium-SCT® uses a non-invasive paste containing ß-emitting particles which are applied directly to a lesion to target cancer cells.3
"The key difference to other therapies is that the Rhenium-SCT® is more precise, allowing the physician to administer treatment locally without damaging surrounding tissue. Patients with difficult anatomic localisations of a tumour, such as ear, nose or anywhere on the face, and those with larger lesions problematic for plastic surgery may benefit from this non-invasive solution, which provides preferrable aesthetic outcomes." adds Dr Gracé.
Shannon D. Brown III, CEO and Managing Director at OncoBeta, says, "This is a significant milestone in the international availability of Rhenium-SCT® for patients in Australia, and yet another step in having Rhenium-SCT® offered in the suite of treatments available to patients suffering with NMSCs."
Sydney Brachytherapy Group is now taking patient referrals from dermatology and skin cancer specialists – for more information please visit: www.sydneybrachytherapy.com or for information about OncoBeta and Rhenium-SCT please visit: www.oncobeta.com
More on Washingtoner
About the Rhenium-SCT® (Skin Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.2 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.6
The Rhenium-SCT® is a painless*, single session†, non-invasive therapy that provides aesthetic results, even in cases otherwise considered difficult to treat.3-5 The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalised therapy that is only applied to the area needed to treat without affecting the healthy tissue. The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patient's skin and the application is safe and simple for the applying physician. Most cases of NMSCs (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT in one single session.†5 Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.5
About OncoBeta®
OncoBeta®, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.
Find out more about the Rhenium-SCT® at www.oncobeta.com
Follow us on social media:
LinkedIn: www.linkedin.com/company/oncobeta-gmbh/
Facebook: www.facebook.com/oncobeta/
More on Washingtoner
Instagram: www.instagram.com/oncobeta_gmbh/
About The Sydney Brachytherapy Group
The Sydney Brachytherapy Group is a multispecialist, multidisciplinary service of healthcare provided at the interventional suites at the North Shore Medical Group. Medical Director, Dr. Joseph Gracé chairs the medical advisory committee of Registered specialist medical practitioners (Visiting Medical Officers or VMO's), who are accredited by that committee. The VMO specialists include Nuclear Physicians, Dermatologists, Plastic Surgeons, Skin Cancer Surgeons and Oncologists. Sydney Brachytherapy is also participating in research and development and contributes to the International OncoBeta Skin Cancer Registry.
Phone: 02 8061 4048
Email: webcontact@sydneybrachytherapy.com
Website: www.sydneybrachytherapy.com
Address: Suite 304, 156-158 Pacific Highway
ST LEONARDS NSW 2065 Australia.
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
*No reported pain3,4
†Complete tumour regression in 98.5% of lesions treated5
References
Rhenium-SCT® is an advanced radionuclide therapy technology that offers a non-invasive, predominantly single-session treatment with improved cosmetic outcomes for patients suffering from Basal Cell and Squamous Cell Carcinomas (BCCs and SCCs). With the global incidence rates of NMSCs increasing, and more than 7.7 million cases of NMSC being recorded each year1,2, this technology offers patients a new treatment option.
Dr Joseph Gracé, Medical Director of Sydney Brachytherapy Group says, "NMSC is a significant health concern here in Australia (especially for those with Fitzpatrick Skin Types I–III), and we are excited to offer Rhenium-SCT® to our patients with NMSC. The non-invasive nature of this treatment, especially for tumours in hard to reach anatomical locations, is one of the main reasons for using Rhenium-SCT®."
Standard treatments for NMSCs typically require surgery, whereas Rhenium-SCT® uses a non-invasive paste containing ß-emitting particles which are applied directly to a lesion to target cancer cells.3
"The key difference to other therapies is that the Rhenium-SCT® is more precise, allowing the physician to administer treatment locally without damaging surrounding tissue. Patients with difficult anatomic localisations of a tumour, such as ear, nose or anywhere on the face, and those with larger lesions problematic for plastic surgery may benefit from this non-invasive solution, which provides preferrable aesthetic outcomes." adds Dr Gracé.
Shannon D. Brown III, CEO and Managing Director at OncoBeta, says, "This is a significant milestone in the international availability of Rhenium-SCT® for patients in Australia, and yet another step in having Rhenium-SCT® offered in the suite of treatments available to patients suffering with NMSCs."
Sydney Brachytherapy Group is now taking patient referrals from dermatology and skin cancer specialists – for more information please visit: www.sydneybrachytherapy.com or for information about OncoBeta and Rhenium-SCT please visit: www.oncobeta.com
More on Washingtoner
- Scott Glickson Joins STS Capital Partners as Managing Director
- Spokane: City Closures Planned for the Thanksgiving Holiday
- BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
- Tacoma: Planning Commission to Hold Public Hearing on December 16 Regarding Proposed Tree and Landscape Code Update
- Enjoy the 2026 holidays with Spokane Parks & Recreation
About the Rhenium-SCT® (Skin Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.2 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.6
The Rhenium-SCT® is a painless*, single session†, non-invasive therapy that provides aesthetic results, even in cases otherwise considered difficult to treat.3-5 The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalised therapy that is only applied to the area needed to treat without affecting the healthy tissue. The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patient's skin and the application is safe and simple for the applying physician. Most cases of NMSCs (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT in one single session.†5 Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.5
About OncoBeta®
OncoBeta®, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.
Find out more about the Rhenium-SCT® at www.oncobeta.com
Follow us on social media:
LinkedIn: www.linkedin.com/company/oncobeta-gmbh/
Facebook: www.facebook.com/oncobeta/
More on Washingtoner
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth
- Auction Finder USA Surpasses 120,000 Live Auction Listings Across All 50 States
- PinnacleQM launches new enterprise website to help Australian organisations deliver more with confidence
- Tacoma: Statement from District 4 Council Member Sandesh Sadalge and At-Large Council Member Olgy Diaz on Sale of Northwest ICE Processing Center to Federal Government
- Loud! OOH Launches UK's First Free Planning Tool for UK Outdoor Advertising Budgets
Instagram: www.instagram.com/oncobeta_gmbh/
About The Sydney Brachytherapy Group
The Sydney Brachytherapy Group is a multispecialist, multidisciplinary service of healthcare provided at the interventional suites at the North Shore Medical Group. Medical Director, Dr. Joseph Gracé chairs the medical advisory committee of Registered specialist medical practitioners (Visiting Medical Officers or VMO's), who are accredited by that committee. The VMO specialists include Nuclear Physicians, Dermatologists, Plastic Surgeons, Skin Cancer Surgeons and Oncologists. Sydney Brachytherapy is also participating in research and development and contributes to the International OncoBeta Skin Cancer Registry.
Phone: 02 8061 4048
Email: webcontact@sydneybrachytherapy.com
Website: www.sydneybrachytherapy.com
Address: Suite 304, 156-158 Pacific Highway
ST LEONARDS NSW 2065 Australia.
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
*No reported pain3,4
†Complete tumour regression in 98.5% of lesions treated5
References
- Global Burden of Disease Cancer Collaboration, et al. JAMA Oncol. 2019;5(12):1749-1768.
- Ciążyńska M, et al. Sci Rep. 2021;11(1):4337.
- Cipriani C, et al. J Dermatolog Treat. 2020; Jul 22:1-7.
- Sedda AF, et al. Clin Exp Dermatol. 2008;33(6):745-749.
- Cipriani C, Sedda AF. Therapeutic Nuclear Medicine, editor Baum RP; New York: Springer, 2014.
- Cancer.net. Skin Cancer (Non-Melanoma): Risk Factors and Prevention. October 2020. https://www.cancer.net/cancer-types/skin-cancer-non-melanoma/risk-factors-and-prevention (accessed March 2022).
Source: OncoBeta GmbH
Filed Under: Health
0 Comments
Latest on Washingtoner
- Smith Strong Merges With Gravis Law, Bringing Gravis Law to Virginia
- Turkish Engineer Who Cracked Wall Street's Algorithm Launches Hermes AI Analyzer
- UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
- The Great Junk Hunt Returns to Puyallup: The Ultimate Holiday Vintage Market is Back!
- Green Revolution CBD Spotlights Its Water-Soluble Focus Tincture With CBD, CBG and Lion's Mane
- Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
- Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
- Coming Up on CNBC: Bilha Wachira Champions Financial Protection During Long-Term Care Awareness Month
- Tacoma: Closures Projected to Allow for Arterial Work
- Tacoma: Applicants Sought for the Bicycle Pedestrian Technical Advisory Group
- Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
- Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand
- Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
- Stamp Me Launches Web App Ahead of 15th Anniversary
- The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
- Spokane City Council Passes Chronic Nuisance Properties Ordinance
- City of Spokane and City Council Announce 2027 Legislative Priorities
- LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
- Security Planning Tips For Your Holiday Event From Access Patrol Services
- Tacoma: Council Member Sandesh Sadalge Focuses Today's District 4 Town Hall on the City's Biennial Budget


